Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “APPETITE DEPRESSANTS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1998

[Appetite depressants and pulmonary hypertension].

In 1996 the total number of prescriptions of the appetite depressant drugs fenfluramine and phentermine exceeded 18 million in the United States. Clinical observation and experimental evidence back in the early 1980's showed that these drugs can cause a pulmonary hypertension. We report the case of a 30-year old woman with a history of seven month medication with dexfenfluramine. She developed severe pulmonary hypertension and right heart failure during late pregnancy. She died of septicemia with multiorgan failure 4 days after cesarean section. Pulmonary hypertension has been reported in association with treatment with fenfluramine and dexfenfluramine. These drugs may cause the increased precapillary resistant pressure through the vasoconstrictor action of serotonin. The typical histological finding is a plexogene pulmonary arteriopathy and valvular heart disease. After these observations the drugs were withdrawn.

Adult↗
PubMed1985

[Chronic pulmonary hypertension of vascular origin, plexogenic pulmonary arteriopathy and the appetite depressant aminorex: addenda to an epidemic].

An epidemic of chronic pulmonary hypertension occurred in Austria, the Federal Republic of Germany, and Switzerland, starting in 1967, peaking in 1968/69, and disappearing after 1972. The mechanism leading to pulmonary hypertension was precapillary vascular obstruction due to plexogenic pulmonary arteriopathy. There was a close geographic and temporal relationship between the epidemic and the marketing and intake of the appetite-depressing drug aminorex fumarate (Menocil). The epidemic was limited to the three above countries where aminorex had been on sale. In the individual patient the symptoms, usually dyspnea, angina pectoris and syncope on exertion, used to follow the beginning of the drug in-take after one year. A similar phase shift could be observed between marketing of the anoretic and the incidence of patients with chronic pulmonary hypertension of vascular origin. The new disease is compared with known forms of pulmonary vascular obstruction. It cannot be distinguished from classical primary pulmonary hypertension or from recurrent silent pulmonary thromboembolism on either clinical or functional grounds; it has plexogenic pulmonary arteriography in common with the former. The prognosis, however, is different: survival is considerably longer in patients with aminorex-associated pulmonary hypertension, and a marked decrease in the pulmonary vascular obstruction after 10 years is no exception. Considering the closeness of the various associations between the event (i.e. the epidemic) and its suspected cause (the anoretic aminorex) from the viewpoint of epidemiological, pharmacological, morphological and prognostic findings and considerations, there is little doubt that aminorex, besides other partly known and partly unknown factors, can in fact favour or cause the development of plexogenic pulmonary arteriography and pulmonary hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗